IDO1

Showing 1 posts of 1 posts found.

BMS pulls the plug on Phase 3 trials of IDO1 inhibitor

May 2, 2018
Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3

Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …

Latest content